Candel Therapeutics (NASDAQ: CADL) net income
Candel Therapeutics reported a net loss of $38.2m for fiscal 2025; in fiscal 2024 it reported a net loss of $55.2m. Earnings per share were −$0.72.
Candel Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$38.2m | — | — | −$0.72 |
| 2024 | −$55.2m | — | — | −$1.74 |
| 2023 | −$37.9m | — | — | −$1.31 |
| 2022 | −$18.8m | — | −15,035.2% | −$0.65 |
| 2021 | −$36.1m | — | −28,899.2% | −$1.91 |
| 2020 | −$17.7m | — | −14,144.0% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Candel Therapeutics net income compared with its sector
By net income for its latest fiscal year, Candel Therapeutics ranks 234th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 232nd | AngioDynamics | −$36.7m | −11.5% |
| 233rd | Sanara Medtech | −$37.6m | −36.4% |
| 234th | Candel Therapeutics | −$38.2m | — |
| 235th | Sight Sciences | −$38.4m | −49.7% |
| 236th | Monte Rosa Therapeutics | −$38.6m | −31.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Candel Therapeutics
- How much did Candel Therapeutics earn in fiscal 2025?
- Candel Therapeutics reported a net loss of $38.2m for fiscal 2025. In fiscal 2024 it reported a net loss of $55.2m.
- What are the earnings per share of Candel Therapeutics?
- They were −$0.72 in fiscal 2025, compared with −$1.74 in fiscal 2024.
- Where does Candel Therapeutics rank in its sector by net income?
- It ranks 234th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Candel Therapeutics come from?
- From the annual report (Form 10-K) that Candel Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Candel Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Candel Therapeutics: the Candel Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.